BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Wedbush cut their Q1 2018 EPS estimates for BioMarin Pharmaceutical in a research report issued on Monday. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will post earnings of ($0.26) per share for the quarter, down from their prior estimate of ($0.17). Wedbush has a “Outperform” rating and a $110.00 price objective on the stock. Wedbush also issued estimates for BioMarin Pharmaceutical’s Q2 2018 earnings at ($0.16) EPS, Q3 2018 earnings at ($0.21) EPS, Q4 2018 earnings at ($0.04) EPS, FY2018 earnings at ($0.68) EPS and FY2019 earnings at $0.52 EPS.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.06). The firm had revenue of $358.31 million for the quarter, compared to the consensus estimate of $346.24 million. BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%.
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) opened at $84.10 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.12 and a current ratio of 2.70. The stock has a market cap of $14,714.36, a price-to-earnings ratio of -125.52 and a beta of 1.74. BioMarin Pharmaceutical has a 1-year low of $77.04 and a 1-year high of $100.51.
In other news, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total transaction of $1,338,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey Robert Ajer sold 2,972 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $82.39, for a total transaction of $244,863.08. Following the transaction, the executive vice president now directly owns 55,332 shares of the company’s stock, valued at $4,558,803.48. The disclosure for this sale can be found here. Insiders have sold a total of 103,827 shares of company stock valued at $9,243,242 over the last ninety days. 1.85% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. First Manhattan Co. lifted its holdings in shares of BioMarin Pharmaceutical by 104.2% during the 4th quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 625 shares during the period. Financial Gravity Companies Inc. bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth about $112,000. Commerce Bank bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $209,000. Teacher Retirement System of Texas bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $220,000. Finally, First Republic Investment Management Inc. bought a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $220,000.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/03/17/q1-2018-eps-estimates-for-biomarin-pharmaceutical-inc-lowered-by-wedbush-bmrn.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.